OTCPicks.com Stocks to Watch for Wednesday, March 21st

OTCPicks Publisher Newsletter

OTCPicks.com Stocks to Watch for Wednesday, March 21st BMTL, RCON, GALE, ROSG, EVCA, ASYI Our Stocks to Watch tomorrow include BioMedical Technology Solutions Holdings Inc. (OTCBB: BMTL), Recon Technology Ltd. (NASDAQ: RCON), Galena Biopharma Inc. (NASDAQ: GALE), Rosetta Genomics Ltd. (NASDAQ: ROSG), EVCARCO Inc. (OTCBB: EVCA) and AISystems Inc. (OTCBB: ASYI).Visit http://otcpicknews.com/emailmarketer/link.phpM940&N93&L1&F=T to register for our Stocks to Watch Newsletter and Email Stock Watch Alerts.BIOMEDICAL TECHNOLOGY SOLUTIONS HOLDINGS (OTCBB: BMTL) “Up 165.38% on Tuesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N93&L52&F=T BioMedical Technology Solutions Holdings, Inc., located in Englewood, Colorado, sells and rents the Demolizer® II through its wholly owned subsidiary BioMedical Technology Solutions, Inc. BMTS` patented Demolizer® Technology converts infectious biomedical waste into non-infectious material. BMTS` products provide biomedical waste treatment solutions for the over 1,000,000 low to medium volume medical waste generators in the US and a global market five times larger than the US. BMTL News:March 15 – BioMedical Technology Solutions Holdings, Inc. Announces a Thirteen Million Dollar Sale to BrazilBioMedical Technology Solutions Holdings, Inc. (OTCBB: BMTL) (“BMTS“) has received a ($13,100,000.00) thirteen million one hundred thousand dollar order for Demolizer II units and Collectors from a distributor in Recife, Brazil including customer orders from the Government agencies of ADAGRO and LACEN. The first units will be delivered within 90 days and the remainder over the course of the next twelve to eighteen months. With this one purchase order alone we anticipate profitability in 2012.The Demolizer® II system is chemical free and environmentally friendly.

It provides automatic generation of state and federal compliance documentation. The system meets or exceeds all EPA and CDC guidelines and is approved or meets treatment requirements in 48 states after review by 80 governmental agencies.Gex “Jay” F. Richardson, President and Chairman of BMTS Holdings, Inc., said, “This order is the culmination of a year long effort in Brazil.

Brazil is a great market for us and this is just the tip of the iceberg for international sales. We are systematically entering other international markets and receiving great success in each market we enter and anticipate more announcements soon.”ABOUT THE DEMOLIZER® IIThe Demolizer® II is the GREEN alternative to biomedical waste disposal.

The device is the only patented, portable, and self-contained system able to process both sharps and typical red bag biomedical waste onsite. The processed waste is rendered sterile and discarded as common trash eliminating up to 100% of the cost associated with its disposal. The Demolizer® II meets or exceeds all EPA and CDC guidelines and is approved or meets treatment requirements in 48 states after review by 80 governmental agencies. The device uses no chemicals or liquids, plugs into a normal outlet through a surge protector, and automatically records and prints state required documentation. The Demolizer® II provides a safer, more environmentally GREEN method for biomedical waste disposal.RECON TECHNOLOGY LIMITED (NASDAQ: RCON) “Up 74.22% on Tuesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N93&L58&F=T Recon Technology, Ltd. is a non-state-owned oil field service company in China. The company has been providing software, equipment and services designed to increase the efficiency and automation in oil and gas exploration, extraction, production and refinery for Chinese oil and gas fields for more than 10 years. RECON News:March 19 – Recon Technology Introduces Baker Hughes Frac-Point™ System to SinopecRecon Technology, Ltd. (NASDAQ: RCON), a Chinese non-state-owned oil and gas automation services provider (the “Company”), announced today that one of its variable interest entities, Beijing BHD Petroleum Technology Co., Ltd. (“BHD”), introduced the Baker Hughes Frac-PointTM System to China Petroleum and Chemical Corporation`s (“Sinopec”) Zhongyuan oilfield. The system helped Sinopec complete the fracturing of a dense sandstone horizontal well that required multistate fracturing. This cooperation positions BHD very well in meeting Sinopec`s further fracturing needs. As of March 19, 2012, BHD has signed several contracts with an accumulated contract value of RMB 30 million (approximately $4.75 million). These contracts will be performed in different stages and are expected to be completed during the first half of 2012.”Our goal is to become a leading oilfield full-service provider by providing safe and efficient products and services to our oilfield clients,” Mr. Chen Guangqiang, Recon`s CTO, said, “Our clients` needs always guide our business development. With further exploration and development of oilfields, the level of reserved crude oil gradually decreases, as does the output. We believe fracturing technology is the most effective way to increase the output and economic benefits of increasingly depleted oilfields. Recon realized early on the importance of the horizontal multistage fracturing technology and established a professional task force to research and test its applicability in China. Our team has engaged in substantial field work across China and abroad to investigate the fracturing technology to meet our long-term clients` needs. We see these contracts as the result of this hard work.””As a smaller company, our strategy is to be the leader of the very specialized oilfield service sector. We aim to improve our technological knowhow and to accumulate experience by cooperating with leading international companies to represent and promote their advanced products in China,” Mr. Chen continued, “Last year we qualified to develop the Frac-Point™ Completion System of Baker Hughes for Zhongyuan Oilfield, a subsidiary of Sinopec. The system is widely used around the world and has been installed in more than 2,200 oil-gas wells, 150 of which are located in China. We assisted Zhongyuan Oilfield last year testing the system in one well and achieved outstanding results. In this case, after the installation of the system, output of oil increased to 6.2 times the previous level and gas production to 4.6 times the previous level. It is our honor to be among the select few domestic suppliers designated by Sinopec of the horizontal multistage fracturing technology. BHD and Sinopec have now signed contracts to provide this technology for ten wells in the Zhongyuan Oilfield.”Mr. Chen also stated, “The horizontal fracturing technology is prioritized in Sinopec`s internal Twelfth Five-Year Plan. Sinopec plans to introduce the fracturing technology to 1,100 of its wells each year over at least the next 3 years. Based on an estimated average investment of RMB 3 million per well, it is a tremendous market of RMB 3.3 billion per year. We will seek to participate in this initiative to the greatest extent possible and improve our service experience, in order to promote this technology and increase our market share in Zhongyuan and other oilfields across China.”GALENA BIOPHARMA INCORPORATED (NASDAQ: GALE) “Up 25.81% on Tuesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N93&L52&F=T Seven Arts Entertainment Inc. is the successor to Seven Arts Pictures Plc., which was founded in 2002 as an independent motion picture production and distribution company engaged in the development, acquisition, financing, production, and licensing of theatrical motion pictures for exhibition in domestic (i.e., the United States and Canada) and foreign theatrical markets, and for subsequent worldwide release in other forms of media, including home video and pay and free television.GALE News:March 20 – Galena Biopharma Strengthens NeuVax™ Intellectual Property Position With Notice of Allowance for U.S. Patent* Patent covers the use of NeuVax for treating Phase 3 target population of low-to-intermediate (IHC 1+/2+) HER2 patients.* Provides NeuVax exclusivity for this indication until 2028, not including any patent term extensions.Galena Biopharma, Inc. (NASDAQ: GALE), a biotechnology company focused on developing innovative, targeted oncology treatments, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent covering the use of its product candidate, NeuVax™, a HER2/neu peptide vaccine, for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC ratings of 1+ or 2+ and a FISH rating of less than about 2.0. These patients represent a significant unmet medical need, with as much as 50-75% of breast cancer patients who do not qualify for Herceptin® therapy.”This NeuVax patent reinforces its pioneering role in advancing treatment to reduce recurrence rates for breast cancer survivors,” stated Mark J.

Ahn, Ph.D., President and CEO. “This addition to our global portfolio allows us to further strengthen our value proposition and explore additional uses for NeuVax to advance care and build value for patients and shareholders.”ABOUT NEUVAX™NeuVax™ is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin(R); Genentech/Roche). NeuVax is an immunotherapy that stimulates the immune system to actively seek out and selectively kill cancer cells. NeuVax directs “killer” T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax has been shown to be most effective in patients with low-to-intermediate HER2/neu expressers with HLA type A2+ or A3+. We believe that approximately 25,000-40,000 of the approximately 200,000 women diagnosed with breast cancer in the United States each year meet these criteria.NeuVax is comprised of two components: a HER2/neu-derived peptide called E75 and the immune adjuvant GM-CSF. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.According to the National Cancer Institute, over 200,000 women in the U.S..

are diagnosed with breast cancer annually. Of these women, about 75% test positive for HER2 (IHC 1+, 2+ or 3+). Only 25% of all breast cancer patients, those with HER2 3+ disease, are eligible for Herceptin(R) (trastuzumab; Roche-Genentech). NeuVax targets the remaining 50% of the low-to-intermediate HER2 breast cancer patients (often referred to as HER2-negative, not eligible for Herceptin) who achieve remission with current standard of care, but have no available HER2-targeted adjuvant treatment options to maintain their disease-free status.ROSETTA GENOMICS LIMITED (NASDAQ: ROSG) “Up 81.19% on Tuesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N93&L34&F=T Rosetta Genomics develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, the company`s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. The Company`s miRview product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.ROSG News:March 20 – Study Published in International Journal of Oncology Shows Potential for microRNAs to Determine Risk of Recurrence in Colorectal CancerRosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study investigating the ability of microRNA expression to determine the risk of disease recurrence in colorectal cancer patients was published in the online edition of the International Journal of Oncology and is expected to appear in the upcoming print edition. The study compared the microRNA (miRNA) profiles in the primary tumor of patients with recurrent and non-recurrent colorectal cancer. The study included 110 patients, 51 (46%) with stage I and 59 (54%) with stage II disease, who underwent curative colectomies without adjuvant therapy and for whom reliable miRNA expression data was available. RNA was extracted from formalin-fixed paraffin-embedded tumor samples. Initial profiling, using microarrays, was done to identify potential biomarkers of recurrence.

The miRNA expression was later verified by quantitative real-time polymerase chain reaction (qRT-PCR). The findings compared the miRNA profiles between patients who had a recurrence within 36 months of surgery (bad prognosis group, n or 21%) and those who did not (good prognosis group, n or 79%) in the entire group and within each stage.In stage II patients, one miRNA, miR-29a, showed a clear differential expression between the good and bad prognosis groups (p=0.028). High expression of miR-29a was associated with a longer disease-free survival on both univariate and multivariate analyses. Using miR-29a, the positive predictive value for non-recurrence was 94% (2 recurrences among 31 patients). The differential expression of miR-29a was verified by qRT-PCR, showing a similar association of this miRNA with disease-free survival. The results showed that none of the 903 miRNAs tested showed differential expression between stage I patients with good and bad prognosis.Commenting on these data, study collaborator, Baruch Brenner, M.D., Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, both in Israel, noted, “The risk of recurrence following successful complete resection is high in stage II and III disease. Consequently, most of these patients will receive additional treatment including postoperative (adjuvant) chemotherapy and preoperative (neoadjuvant) or postoperative (adjuvant) chemo-radiotherapy. However, the majority of patients receiving neoadjuvant and/or adjuvant therapy, which are associated with significant morbidity and even long-term sequelae and mortality, do not need it.”Dr. Brenner continued, “The current study suggests a potential prognostic role of miR-29a in patients with resected stage II colon cancer. Patients who did not experience a recurrence within three years from the resection of their primary tumor had significantly higher expression levels of this miRNA compared with patients who did have a recurrence within the same time. To further support the prognostic role of miR-29a, high expression levels of this miRNA correlated not only with the risk of recurrence, but also with the duration of disease-free survival.””Current methods for stratifying patients with colorectal cancer by their prognosis are still mainly based on the extent of the local tumor spread and do little to distinguish between patients who do and those who do not need additional treatment,” stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “Colorectal cancer is one of the most common cancers. Globally, more than 500,000 people die of this disease each year, making it the third most common cancer death worldwide. Data from this study demonstrate that miR-29a has the potential to serve as a biomarker of the risk of recurrence in stage II colon cancer, a finding that may have important implications for patient care. Informed decision-making using a test with a high positive predictive value may spare patients unnecessary and sometimes toxic post-surgery treatment, and may identify which patients to treat more aggressively.”ABOUT MIRVIEW® PRODUCTSmiRview® are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRview® mets and miRview® mets² accurately identify the primary tumor type in primary and metastatic cancer including Cancer of Unknown Primary (CUP). miRview® squamous accurately identifies the squamous subtype of non-small cell lung cancer, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain therapies. miRview® meso diagnoses mesothelioma, a cancer connected to asbestos exposure. miRview® lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells.

miRview® tests are designed to provide objective diagnostic data; it is the treating physician`s responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview® mets and miRview® mets2 test, 60,000 from miRview® squamous, 60,000 from miRview® meso and more than 1 million patients worldwide from miRview lung. The Company`s tests are offered directly by Rosetta Genomics in the U.S., and through distributors around the globe. ABOUT MICRORNASmicroRNAs (miRNAs) are recently discovered, small RNAs that act as master regulators of protein synthesis, and have been shown to be highly effective biomarkers. The unique advantage of microRNAs as biomarkers lies in their high tissue specificity, and their exceptional stability in the most routine preservation methods for biopsies, including Formalin Fixed Paraffin Embedded (FFPE) block tissue and fine needle aspirate (FNA) cell blocks. It has been suggested that their small size (19 to 21 nucleotides) enables them to remain intact in FFPE blocks, as opposed to messenger RNA (mRNA), which tends to degrade rapidly. In addition, early preclinical data has shown that by controlling the levels of specific microRNAs, cancer cell growth may be reduced. EVCARCO INCORPORATED (OTC: EVCA) “Up 100.00% on Tuesday”Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N93&L52&F=T EVCARCO, Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles from multiple manufactures. EVCARCO — Future Driven®EVCA News:February 22 – EVCARCO, Inc. Signs a Memorandum of Understanding With HFX, Inc.EVCARCO, Inc. (OTCBB: EVCA) announced that the Company has signed a Memorandum of Understanding (MOU) with HFX Laboratories, Inc. regarding the market development, testing and licensing of the HFX4 Hydrogen Hybrid Combustion/Fuel Enhancement Systems.EVCA will establish retail distribution for the HFX4 System through its dealerships and showrooms upon completion of Due Diligence. The HFX4 Hybrid System is a unique product that produces hydrogen gas for use as a catalyst in the vehicle`s combustion system. The hydrogen catalyst is introduced into the vehicle`s air intake to completely utilize the fuel in the combustion process.Mack Sanders, CEO of EVCARCO, remarked, “With gasoline prices reaching $4.00 a gallon in some areas and projected to go higher, the HFX4 System is a perfect fit for after-market vehicles. The HFX4 Hybrid System seems to be easy to install on an existing vehicle, improves performance, and claims to provide an increase in MPG and reduction in emissions. Upon completion of the Due Diligence, a Definitive Licensing Distribution Agreement will be entered into for the U.S., Canada, Mexico and Russia. The goal is to find in our Due Diligence, results of 20% to 35% improvement in MPG and a reduction in emissions in the range of 60% depending on engine efficiency..AISYSTEMS INCORPORATED (OTCBB: ASYI) “Up 131.25% on Tuesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N93&L97&F=T AISystems has developed a unique, proprietary business platform software system for the airline industry called jetEngine™, which is comprised of systems and mathematical algorithms capable of generating significant profitability improvements through strategic business planning capabilities, resource scheduling, revenue management and integrated operations. ASYI News:No recent news for AISystems, Inc. (OTCBB: ASYI).OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it..DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies. The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them. Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing. Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company`s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company`s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company`s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://otcpicknews.com/emailmarketer/link.phpM940&N93&L=7&F=T and FINRA at http://otcpicknews.com/emailmarketer/link.phpM940&N93&L=8&F=T. Disclosure: OTCPicks.com and affiliates have been not been compensated by any of the companies covered in this release.

Related posts:

1. OTCPicks.com Daily Market Movers Digest Midday Report for Tuesday, March 20th
2. OTCPicks.com Daily Market Movers Digest Midday Report for Friday, December 2nd
3. OTCPicks.com Daily Market Movers Digest Midday Report for Monday, February 13th
4. OTCPicks.com Daily Market Movers Digest Midday Report for Wednesday, February 2nd
5. OTCPicks.com Daily Market Movers Digest Midday Report for Thursday, February 16th